ADVFN ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Swedish Orphan Biovitrum AB (PK)

Swedish Orphan Biovitrum AB (PK) (SWOBY)

24,01
0,00
( 0,00% )
Aktualisiert: 17:20:27

Swedish Orphan Biovitrum AB (PK) (SWOBY) Aktie

Professionelle Tools für Privatanleger.

Premium

Wichtige Statistiken und Details

Current Price
24,01
( - )
Gebot
24,10
Fragen
26,18
Volumen
3
0,00 Tagesbereich 0,00
13,57 52-Wochen-Bereich 29,32
Marktkapitalisierung
Handelsende
24,01
Handelsbeginn
-
Letzte Trade
3
@
25.105
Letzter Handelszeitpunkt
16:10:35
Finanzvolumen
-
VWAP
-
Durchschnittliches Volumen (3 Mio.)
US$ 430.153
Ausgegebene Aktien
345.845.189
Dividendenrendite (LTM)
Kurs-Gewinn-Verhältnis
176,65
Gewinn pro Aktie (EPS)
2,64
Erlöse (LTM)
28,96B
Nettogewinn (LTM)
921M

Über Swedish Orphan Biovitrum AB (PK)

Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care. It offers ... Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care. It offers Alprolix for haemophilia B; ALTUVOCT for the treatment and prophylaxis of bleeding in patients with haemophilia A; Aspaveli/Empaveli for treating adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet for the treatment of immune thrombocytopenia and thrombocytopenia; Elocta/Eloctate for the treatment and prophylaxis of bleeding in patients with haemophilia A; Gamifant for treating hemophagocytic lymphohistiocytosis; Kineret for the treatment of cryopyrin-associated periodic syndrome, rheumatoid arthritis, familial Mediterranean fever, deficiency of interleukin-1 receptor antagonist, and systemic juvenile idiopathic arthritis; Orfadin for hereditary tyrosinemia type 1 and alkaptonuria; Synagis for the prevention of serious lower respiratory tract infection caused by respiratory syncytial virus in infants and young children; VONJO, a kinase inhibitor indicated for the treatment of post-polycythemia vera or post-essential thrombocythemia myelofibrosis; and Zynlonta for treating adult patients with relapsed or refractory diffuse large and high grade B-cell lymphoma. The company also provides other medicines, such as Akynzeo, Jyseleca, Tegsedi, and Waylivra, as well as develops drug substances for ReFacto AF/Xyntha for Pfizer. The company has collaboration agreements with Sanofi, Apellis Pharmaceuticals, Inc., ADC Therapeutics SA, and Cartesian Therapeutics, Inc. The company was incorporated in 1939 and is headquartered in Stockholm, Sweden. Mehr anzeigen

Sektor
-
Branche
-
Website
Hauptsitz
Stockholm, Sweden
Gegründet
2026
Swedish Orphan Biovitrum AB (PK) is listed in the sector of the OTC Markets with ticker SWOBY. The last closing price for Swedish Orphan Biovitrum... (PK) was US$24,01. Over the last year, Swedish Orphan Biovitrum... (PK) shares have traded in a share price range of US$ 13,57 to US$ 29,32.

Swedish Orphan Biovitrum... (PK) currently has 345.845.189 shares in issue. The market capitalisation of Swedish Orphan Biovitrum... (PK) is US$8,30 billion. Swedish Orphan Biovitrum... (PK) has a price to earnings ratio (PE ratio) of 176.65.

SWOBY Neueste Nachrichten

Keine Nachrichten vorhanden.
Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
1-0.05-0.20781379883624.0624.22335923.31651143DR
40.190.79764903442523.8224.22239323.32777809DR
122.4511.363636363621.5629.3221.5665824.06838178DR
264.4622.813299232719.5529.3216.992521.6694542DR
528.58555.656401944915.42529.3213.57115518.07321539DR
15614.74159.0075512419.2729.329.27177214.58513753DR
26013.6726132.26343181110.337429.329.27176314.58392712DR

SWOBY - Frequently Asked Questions (FAQ)

What is the current Swedish Orphan Biovitrum AB (PK) share price?
The current share price of Swedish Orphan Biovitrum AB (PK) is US$ 24,01
How many Swedish Orphan Biovitrum AB (PK) shares are in issue?
Swedish Orphan Biovitrum AB (PK) has 345.845.189 shares in issue
What is the market cap of Swedish Orphan Biovitrum AB (PK)?
The market capitalisation of Swedish Orphan Biovitrum AB (PK) is USD 8,3B
What is the 1 year trading range for Swedish Orphan Biovitrum AB (PK) share price?
Swedish Orphan Biovitrum AB (PK) has traded in the range of US$ 13,57 to US$ 29,32 during the past year
What is the PE ratio of Swedish Orphan Biovitrum AB (PK)?
The price to earnings ratio of Swedish Orphan Biovitrum AB (PK) is 176,65
What is the cash to sales ratio of Swedish Orphan Biovitrum AB (PK)?
The cash to sales ratio of Swedish Orphan Biovitrum AB (PK) is 5,57
What is the registered address of Swedish Orphan Biovitrum AB (PK)?
The registered address for Swedish Orphan Biovitrum AB (PK) is Norra Stationsgatan 93A, Stockholm, Stockholm County
What is the Swedish Orphan Biovitrum AB (PK) website address?
The website address for Swedish Orphan Biovitrum AB (PK) is www.sobi.com

SWOBY Trades

Mehr

Trades verzögert

Um Echtzeit-Trades zu erhalten, aktualisieren Sie Ihr Konto

Auf Echtzeit aktualisieren
Keine Diskussionen Gefunden.
Neuen Thread Erstellen